$HLYK
HealthLynked Corp Stock $hlyk

$hlyk Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025432 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.755M	$1.155M	$5.858M
YoY Change	9.23%	-30.33%	-36.31%
Cost Of Revenue	$656.3K	$713.2K	$3.029M
YoY Change	-9.28%	3.22%	2.49%
Gross Profit	$1.099M	$442.0K	$2.829M
YoY Change	24.39%	-54.3%	-54.68%
Gross Profit Margin	62.61%	38.26%	48.29%
Selling, General & Admin	$1.104M	$1.890M	$4.577M
YoY Change	-46.24%	-9.03%	-43.1%
% of Gross Profit	100.45%	427.6%	161.81%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$88.08K	$207.2K	$829.5K
YoY Change	-56.8%	1.42%	0.22%
% of Gross Profit	8.02%	46.87%	29.32%
Operating Expenses	$2.812M	$1.295M	$14.52M
YoY Change	13.16%	-48.98%	28.64%
Operating Profit	-$1.057M	-$852.7K	-$8.659M
YoY Change	-34.02%	-45.7%	71.7%
Interest Expense	$11.38K	$72.49K	$591.9K
YoY Change	-97.37%	-149.98%	-243.65%
% of Operating Profit
Other Income/Expense, Net	-$11.38K		-$22.83K
YoY Change	126.58%		19.23%
Pretax Income	-$1.178M	-$3.526M	-$8.067M
YoY Change	0.83%	105.54%	-22.52%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	$1.452M	-$4.362M	-$8.816M
YoY Change	-224.3%	154.31%	-15.34%
Net Earnings / Revenue	82.72%	-377.66%	-150.49%
Basic Earnings Per Share	$0.00		-$0.04
Diluted Earnings Per Share	$0.00	-$0.01	-$0.04
COMMON SHARES
Basic Shares Outstanding	259.2M shares	254.4M shares	243.4M shares
Diluted Shares Outstanding	257.1M shares		243.4M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.67K	$61.89K	$61.89K
YoY Change	-96.44%	-98.12%	-98.12%
Cash & Equivalents	$68.67K	$61.89K
Short-Term Investments
Other Short-Term Assets	$1.713M	$1.548M	$1.548M
YoY Change	1898.52%	1024.61%	1024.61%
Inventory	$192.9K	$192.8K	$192.8K
Prepaid Expenses	$1.500K
Receivables	$48.97K	$72.28K	$342.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.241M	$2.145M	$2.145M
YoY Change	-0.2%	-41.25%	-41.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$382.1K	$413.1K	$953.3K
YoY Change	-54.87%	17.87%	8.67%
Goodwill	$320.0K	$320.0K
YoY Change	-58.24%	-72.13%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.707M	$50.91K	$50.91K
YoY Change	1210.83%	-63.28%	-63.28%
Total Long-Term Assets	$3.904M	$2.436M	$2.436M
YoY Change	-42.81%	-65.42%	-65.42%
TOTAL ASSETS
Total Short-Term Assets	$2.241M	$2.145M	$2.145M
Total Long-Term Assets	$3.904M	$2.436M	$2.436M
Total Assets	$6.145M	$4.581M	$4.581M
YoY Change	-32.26%	-57.17%	-57.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.364M	$1.603M	$1.603M
YoY Change	79.43%	102.64%	102.64%
Accrued Expenses	$267.1K	$344.5K	$344.5K
YoY Change	-9.29%	19.2%	19.2%
Deferred Revenue	$575.8K	$574.8K
YoY Change		689.21%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$221.7K	$321.7K	$321.7K
YoY Change	522.17%	425.14%	425.14%
Total Short-Term Liabilities	$3.307M	$3.475M	$3.475M
YoY Change	89.8%	81.17%	81.17%
LONG-TERM LIABILITIES
Long-Term Debt	$37.50K	$45.00K	$495.0K
YoY Change	-93.2%	-55.56%	-10.2%
Other Long-Term Liabilities	$182.4K	$296.6K	$296.6K
YoY Change	-71.24%	-70.97%	-70.97%
Total Long-Term Liabilities	$37.50K	$45.00K	$791.6K
YoY Change	-96.84%	-55.56%	-49.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.307M	$3.475M	$3.475M
Total Long-Term Liabilities	$37.50K	$45.00K	$791.6K
Total Liabilities	$3.977M	$4.266M	$4.266M
YoY Change	35.82%	22.22%	22.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.57M	-$41.02M
YoY Change		27.37%
Common Stock	$25.92K	$25.59K
YoY Change		7.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.169M	$314.5K	$314.5K
YoY Change
Total Liabilities & Shareholders Equity	$6.145M	$4.581M	$4.581M
YoY Change	-32.26%	-57.17%	-57.17%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$1.452M	-$4.362M	-$8.816M
YoY Change	-224.3%	154.31%	-15.34%
Depreciation, Depletion And Amortization	$88.08K	$207.2K	$829.5K
YoY Change	-56.8%	1.42%	0.22%
Cash From Operating Activities	-$1.100M	-$600.4K	-$4.363M
YoY Change	-18.13%	-71.98%	15.73%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$23.56K
YoY Change		-100.0%	-222.41%
Acquisitions	$1.312M		$313.8K
YoY Change
Other Investing Activities	$781.4K	$0.00	-$521.2K
YoY Change			61.8%
Cash From Investing Activities	$781.4K	$0.00	-$544.8K
YoY Change	-3650.12%	-100.0%	59.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$956.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$324.9K	504.1K	$1.678M
YoY Change		-6646.88%	-76.83%
NET CHANGE
Cash From Operating Activities	-$1.100M	-600.4K	-$4.363M
Cash From Investing Activities	$781.4K	0.000	-$544.8K
Cash From Financing Activities	$324.9K	504.1K	$1.678M
Net Change In Cash	$6.775K	-96.27K	-$3.230M
YoY Change		-95.54%	-203.2%
FREE CASH FLOW
Cash From Operating Activities	-$1.100M	-$600.4K	-$4.363M
Capital Expenditures		$0.00	$23.56K
Free Cash Flow	-$1.100M	-$600.4K	-$4.387M
YoY Change	-16.76%	-71.89%	16.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55768
CY2022	dei	Entity Registrant Name EntityRegistrantName	HealthLynked Corp.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1634127
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1265 Creekside Parkway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34108
CY2022	dei	City Area Code CityAreaCode	(800)
CY2022	dei	Local Phone Number LocalPhoneNumber	928-7144
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	16365786	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	259152889	shares
CY2022	dei	Auditor Name AuditorName	RBSM LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022	dei	Auditor Firm AuditorFirmId	587
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	61891	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3291646	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72284	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	86287	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	192833	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	134930	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	269736	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92940	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	137630	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	1454856	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2144540	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3650493	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	283512	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413123	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	350482	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1112007	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3807121	usd
CY2022Q4	us-gaap	Goodwill Goodwill	319958	usd
CY2021Q4	us-gaap	Goodwill Goodwill	766249	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	540181	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	526730	usd
CY2022Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	50907	usd
CY2021Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	138625	usd
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	1454856	usd
CY2022Q4	us-gaap	Assets Assets	4580716	usd
CY2021Q4	us-gaap	Assets Assets	10694556	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1602558	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	790843	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	574847	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47838	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	344464	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	288966	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	104490	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	506110	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	300600	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	291650	usd
CY2022Q4	hlyk	Liabilityclassified Equity Instruments Current Portion LiabilityclassifiedEquityInstrumentsCurrentPortion	30000	usd
CY2021Q4	hlyk	Liabilityclassified Equity Instruments Current Portion LiabilityclassifiedEquityInstrumentsCurrentPortion	61250	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	100068	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	403466	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	25000	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	25000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3474697	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1917963	usd
CY2022Q4	hlyk	Government And Vendor Notes Payable Long Term Portion GovernmentAndVendorNotesPayableLongTermPortion	450000	usd
CY2021Q4	hlyk	Government And Vendor Notes Payable Long Term Portion GovernmentAndVendorNotesPayableLongTermPortion	450000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	45000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	101250	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	98239	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	782224	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198330	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239225	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4266266	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3490662	usd
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	237893473	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	237893473	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	25594	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	23789	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2750	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	2750	usd
CY2022Q4	hlyk	Common Stock Issuable Value CommonStockIssuableValue	225584	usd
CY2021Q4	hlyk	Common Stock Issuable Value CommonStockIssuableValue	282347	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41081455	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39100197	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41020933	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32205189	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	314450	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7203894	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4580716	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10694556	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5407416	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5764186	usd
CY2022	hlyk	Subscription Consulting And Event Revenue SubscriptionConsultingAndEventRevenue	-20835	usd
CY2021	hlyk	Subscription Consulting And Event Revenue SubscriptionConsultingAndEventRevenue	-14883	usd
CY2022	hlyk	Product Revenue ProductRevenue	429951	usd
CY2021	hlyk	Product Revenue ProductRevenue	718062	usd
CY2022	us-gaap	Revenues Revenues	5858202	usd
CY2021	us-gaap	Revenues Revenues	6497131	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3335695	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3114991	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2566191	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2349279	usd
CY2022	hlyk	Cost Of Product Revenue CostOfProductRevenue	463156	usd
CY2021	hlyk	Cost Of Product Revenue CostOfProductRevenue	606521	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4577490	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4929668	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	829481	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	827696	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2745563	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14517576	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11828155	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8659374	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5331024	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4957168	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-19246	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	110000	usd
CY2022	hlyk	Amortization Of Original Issue Discounts On Notes Payable AmortizationOfOriginalIssueDiscountsOnNotesPayable	-55282	usd
CY2022	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	779999	usd
CY2021	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-373656	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22825	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19144	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	591892	usd
CY2022	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5369214	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8067482	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10700238	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8067482	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10700238	usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-748262	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	287656	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10412582	usd
CY2022	hlyk	Deemed Dividend Amortization Of Beneficial Conversion Feature DeemedDividendAmortizationOfBeneficialConversionFeature	353571	usd
CY2021	hlyk	Deemed Dividend Amortization Of Beneficial Conversion Feature DeemedDividendAmortizationOfBeneficialConversionFeature	353571	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9169315	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10766153	usd
CY2022	hlyk	Netlosspersharetocommonshareholdersbasic Netlosspersharetocommonshareholdersbasic	-0.03
CY2021	hlyk	Netlosspersharetocommonshareholdersbasic Netlosspersharetocommonshareholdersbasic	-0.05
CY2022	hlyk	Netlosspersharetocommonshareholdersdiluted Netlosspersharetocommonshareholdersdiluted	-0.03
CY2021	hlyk	Netlosspersharetocommonshareholdersdiluted Netlosspersharetocommonshareholdersdiluted	-0.05
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243419736	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	224658709	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	243419736	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	224658709	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1350008	usd
CY2021	hlyk	Sale Of Common And Preferred Stock In Exchange For Marketable Securities SaleOfCommonAndPreferredStockInExchangeForMarketableSecurities	4769869	usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2179412	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	366300	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4061548	usd
CY2021	hlyk	Fair Value Of Warrants Issued And Modified In Connection With Conversion And Retirement Of Conve FairValueOfWarrantsIssuedAndModifiedInConnectionWithConversionAndRetirementOfConve	3201138	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	43235	usd
CY2021	hlyk	Consultant Fees Payable With Common Shares And Warrants ConsultantFeesPayableWithCommonSharesAndWarrants	487278	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	200966	usd
CY2021	hlyk	Exerciseofwarrants Exerciseofwarrants	947972	usd
CY2021	hlyk	Exercise Of Stock Options Value ExerciseOfStockOptionsValue	16450	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	7700	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10412582	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7203894	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	451203	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	100000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	570349	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	214651	usd
CY2022	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt FairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt	35281	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	103804	usd
CY2022	hlyk	Consultant Fees Payable With Common Shares And Warrants ConsultantFeesPayableWithCommonSharesAndWarrants	321301	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	129711	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	314450	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10412582	usd
CY2022	hlyk	Income Loss From Discontinued Operations IncomeLossFromDiscontinuedOperations	-748262	usd
CY2021	hlyk	Income Loss From Discontinued Operations IncomeLossFromDiscontinuedOperations	287656	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	829481	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	827696	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2745563	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	439763	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	742729	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	55282	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	100000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4957168	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-19246	usd
CY2022	hlyk	Gain Losses On Change In Fair Value Of Contingent Acquisition Consideration GainLossesOnChangeInFairValueOfContingentAcquisitionConsideration	779999	usd
CY2021	hlyk	Gain Losses On Change In Fair Value Of Contingent Acquisition Consideration GainLossesOnChangeInFairValueOfContingentAcquisitionConsideration	-373656	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-36510	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14632	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	44631	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39730	usd
CY2022	hlyk	Increase Decrease In Contract Assets IncreaseDecreaseInContractAssets	269736	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-51532	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	48063	usd
CY2022	hlyk	Increase Decrease In Right Of Use Lease Assets IncreaseDecreaseInRightOfUseLeaseAssets	351718	usd
CY2021	hlyk	Increase Decrease In Right Of Use Lease Assets IncreaseDecreaseInRightOfUseLeaseAssets	109587	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	701605	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-138716	usd
CY2022	hlyk	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	350566	usd
CY2021	hlyk	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	114254	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	527010	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6277	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3673950	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4019274	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-689070	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	249420	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4363020	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3769854	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	313802	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	207384	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	322106	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23564	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19250	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-544750	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-341356	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-544750	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-341356	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	956787	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6949281	usd
CY2021	hlyk	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	350200	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	943300	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	222072	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	51109	usd
CY2021	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	7700	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1678015	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7240672	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1678015	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7240672	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3229755	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3129462	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3291646	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	162184	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61891	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3291646	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5923	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	232	usd
CY2022	hlyk	Fair Value Of Shares Issued As Purchase Price Consideration FairValueOfSharesIssuedAsPurchasePriceConsideration	103804	usd
CY2022	hlyk	Common Stock To Be Issued Now Issued CommonStockToBeIssuedNowIssued	305069	usd
CY2021	hlyk	Common Stock To Be Issued Now Issued CommonStockToBeIssuedNowIssued	262273	usd
CY2022	hlyk	Net Carrying Value Of Equity Liabilitiesassets Written Off NetCarryingValueOfEquityLiabilitiesassetsWrittenOff	428859	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	284905	usd
CY2022	hlyk	Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote	279415	usd
CY2022	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Debt FairValueOfWarrantsAllocatedToProceedsOfDebt	35281	usd
CY2022	hlyk	Debt Discount And Original Issue Discount Allocated To Proceeds Of Notes Payable DebtDiscountAndOriginalIssueDiscountAllocatedToProceedsOfNotesPayable	153631	usd
CY2021	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	632826	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	43236	usd
CY2021Q4	hlyk	Incremental Fair Value Of Warrants Modified To Extend Maturity Date Of Convertible Notes Payable IncrementalFairValueOfWarrantsModifiedToExtendMaturityDateOfConvertibleNotesPayable	126502	usd
CY2021	hlyk	Conversion Of Convertible Notes Payable To Common Stock ConversionOfConvertibleNotesPayableToCommonStock	4061549	usd
CY2021Q4	hlyk	Fair Value Of Warrants Issued In Connection With Conversion Of Convertible Notes Payable FairValueOfWarrantsIssuedInConnectionWithConversionOfConvertibleNotesPayable	3074637	usd
CY2021	hlyk	Accrued Liabilities Relieved Upon Cashless Exercise Of Warrants AccruedLiabilitiesRelievedUponCashlessExerciseOfWarrants	614221	usd
CY2021	hlyk	Contingent Acquisition Consideration Payable In Common Stock ContingentAcquisitionConsiderationPayableInCommonStock	366300	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	165000	usd
CY2014Q3	hlyk	Number Of Authorized Shares NumberOfAuthorizedShares	250000000	shares
CY2014Q3	hlyk	Shares Of Common Stock SharesOfCommonStock	230000000	shares
CY2014Q3	hlyk	Shares Of Preferred Stock SharesOfPreferredStock	20000000	shares
CY2018Q1	hlyk	Increase Amount Of Authorized Shares Of Common Stock IncreaseAmountOfAuthorizedSharesOfCommonStock	500000000	shares
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets, cash flow and fair value assumptions associated with measurements of contingent acquisition consideration and impairment of intangible assets and goodwill, valuation of inventory, collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2022	us-gaap	Insured Event Gain Loss InsuredEventGainLoss	0	usd
CY2021	us-gaap	Insured Event Gain Loss InsuredEventGainLoss	2957040	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	98180	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	193363	usd
CY2022Q4	hlyk	Net Patient Services Accounts Receivable NetPatientServicesAccountsReceivable	49777	usd
CY2021Q4	hlyk	Net Patient Services Accounts Receivable NetPatientServicesAccountsReceivable	86287	usd
CY2022	us-gaap	Accounts Receivable Sale AccountsReceivableSale	22506	usd
CY2021	us-gaap	Accounts Receivable Sale AccountsReceivableSale	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	13972	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentrations of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2022	hlyk	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2022Q4	us-gaap	Cash Cash	61891	usd
CY2022	hlyk	Working Capital Deficit WorkingCapitalDeficit	1330157	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41020933	usd
CY2022	hlyk	Net Loss NetLoss	8815744	usd
CY2022	hlyk	Net Cash Used In Operating Activities NetCashUsedInOperatingActivities	4363020	usd
CY2022	us-gaap	Payments For Proceeds From Hedge Financing Activities PaymentsForProceedsFromHedgeFinancingActivities	-1678015	usd
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.0001
CY2022Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	561000	usd
CY2022	hlyk	Payment Of Promissory Note paymentOfPromissoryNote	392700	usd
CY2022Q4	us-gaap	Transfer Of Financial Assets Accounted For As Sales Cash Proceeds Received For Assets Derecognized Amount TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount	279415	usd
CY2022	hlyk	Unpaid Principal unpaidPrincipal	168300	usd
CY2022	hlyk	Debt Instrument Agreement Amount DebtInstrumentAgreementAmount	750000	usd
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	3000000	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	500000	usd
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	2250000	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	339865	usd
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	2700861	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1088127	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2413205	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-748262	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	287656	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-748262	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	287656	usd
CY2022	hlyk	Division Amount DivisionAmount	-689070	usd
CY2021	hlyk	Division Amount DivisionAmount	249420	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	97648	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	319958	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6127394	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6999442	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	5930867	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	10253074	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Current DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent	1073000	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent	381856	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1454856	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent	1073000	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent	381856	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	1454856	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	1454856	usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	1454856	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	25000	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	25000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	25000	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	25000	usd
CY2022	hlyk	Terms Of Acquisition Description TermsOfAcquisitionDescription	Under the terms of acquisition, the Company paid AEU equity holders consideration of (i) $139,923 cash (less $11,198 cash on hand at AEU as of the closing date), (ii) payment in cash of direct financial obligation of AEU on, or in close proximity to, the date of the business combination, in the amount of $185,077, and (iii) 792,394 shares of Company common stock at closing with a fair value of $103,804 determined using the average closing price of the Company’s common shares for the five days preceding the acquisition date. The total consideration fair value represents a transaction value of $417,606.
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	103804	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	139923	usd
CY2022	hlyk	Payment Of Aeu Debt Obligations In Cash PaymentOfAEUDebtObligationsInCash	185077	usd
CY2022Q4	hlyk	Acquisition Cash Received AcquisitionCashReceived	11198	usd
CY2022Q4	hlyk	Acquisition Of Fair Value Total Consideration AcquisitionOfFairValueTotalConsideration	417606	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	13272	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	152759	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	80264	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	33037	usd
CY2022Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	35346	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	80264	usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	hlyk	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6 – PREPAID EXPENSES AND OTHER</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Prepaid and other expenses as of December 31, 2022 and 2021 were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Insurance prepayments</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,020</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other expense prepayments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,860</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deferred equity compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total prepaid expenses and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,255</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: long term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,907</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(138,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Prepaid expenses and other, current portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">92,940</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">137,630</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deferred equity compensation reflects common stock grants made in 2021 and 2022 from the Company’s 2021 Equity Incentive Plan that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. The original grant date fair value of the equity compensation was $90,000 and $165,000 in the years ended December 31, 2022 and 2021, respectively. Amortization was $46,771 and $13,750, respectively, in the years ended December 31, 2022 and 2021, respectively. At inception, the Company recorded a corresponding liability captioned “Liability-classified equity instruments.”</span></p>
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	17733	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	25020	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6989	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	50860	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	44125	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	49125	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	75000	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	151250	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	143847	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	276255	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	50907	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	138625	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	92940	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	137630	usd
CY2022Q4	us-gaap	Compensation And Benefits Trust CompensationAndBenefitsTrust	90000	usd
CY2021Q4	us-gaap	Compensation And Benefits Trust CompensationAndBenefitsTrust	165000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	46771	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	13750	usd
CY2022Q4	us-gaap	Area Of Land AreaOfLand	4000	sqm
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	810317	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	633994	usd
CY2022Q4	hlyk	Accumulated Depreciation AccumulatedDepreciation	397194	usd
CY2021Q4	hlyk	Accumulated Depreciation AccumulatedDepreciation	283512	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413123	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	350482	usd
CY2022	us-gaap	Depreciation Depreciation	113681	usd
CY2021	us-gaap	Depreciation Depreciation	106055	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1142538	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4680538	usd
CY2022Q4	hlyk	Accumulated Amortization AccumulatedAmortization	30531	usd
CY2021Q4	hlyk	Accumulated Amortization AccumulatedAmortization	873417	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1112007	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3807121	usd
CY2022Q4	us-gaap	Goodwill Goodwill	319958	usd
CY2021Q4	us-gaap	Goodwill Goodwill	766249	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	715800	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	721641	usd
CY2022Q4	us-gaap	Reporting Unit Amount Of Fair Value In Excess Of Carrying Amount ReportingUnitAmountOfFairValueInExcessOfCarryingAmount	2745563	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1979314	usd
CY2022	hlyk	Intangible Asset Goodwill IntangibleAssetGoodwill	766249	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company has separate operating leases for office space related to its NWC, NCFM, BTG and AEU practices, two separate leases relating to its corporate headquarters, and a copier lease that expire in July 2023, May 2025, March 2023, March 2026, November 2023, November 2023 and January 2027, respectively.
CY2022	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	As of December 31, 2022, the Company’s weighted-average remaining lease term relating to its operating leases was 2.0 years, with a weighted-average discount rate of 10.32%.
CY2022	hlyk	Operating Leases OperatingLeases	three
CY2022Q4	hlyk	Operating Lease Assets OperatingLeaseAssets	540181	usd
CY2021Q4	hlyk	Operating Lease Assets OperatingLeaseAssets	526730	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	344464	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	288966	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198330	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239225	usd
CY2022Q4	hlyk	Operating Lease Liabilities OperatingLeaseLiabilities	542794	usd
CY2021Q4	hlyk	Operating Lease Liabilities OperatingLeaseLiabilities	528191	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	430719	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	341453	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	863662	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	306220	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	190633	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	172500	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	482296	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	250577	usd
CY2022Q4	hlyk	Accrued Settlement Of Litigation And Others Dispute AccruedSettlementOfLitigationAndOthersDispute	63615	usd
CY2021Q4	hlyk	Accrued Settlement Of Litigation And Others Dispute AccruedSettlementOfLitigationAndOthersDispute	46712	usd
CY2022Q4	hlyk	Product Return Allowance1 ProductReturnAllowance1	2352	usd
CY2021Q4	hlyk	Product Return Allowance1 ProductReturnAllowance1	14834	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1602558	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	790843	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	574847	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	47838	usd
CY2022	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	269736	usd
CY2021	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	0	usd
CY2022Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	300600	usd
CY2021Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	300600	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	205510	usd
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	506110	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	300600	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	20000	usd
CY2022	hlyk	Compensation Arrangements CompensationArrangements	402144	usd
CY2021	hlyk	Compensation Arrangements CompensationArrangements	399912	usd
CY2022Q4	hlyk	Disaster Relief Loans DisasterReliefLoans	450000	usd
CY2021Q4	hlyk	Disaster Relief Loans DisasterReliefLoans	450000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	168300	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	129705	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	31393	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	779398	usd
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	450000	usd
CY2022Q4	hlyk	Unamortized Discount UnamortizedDiscount	37748	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	741650	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	450000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	450000	usd
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	450000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	291650	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	632826	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	6503	usd
CY2020Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P30Y
CY2022Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	550000	usd
CY2022Q3	hlyk	Discount Percentage DiscountPercentage	0.05	pure
CY2022Q3	hlyk	Interest Rate Percentage InterestRatePercentage	0	pure
CY2022Q3	hlyk	Repaid Cash Premium Percentage RepaidCashPremiumPercentage	0.02	pure
CY2022Q3	us-gaap	Cash Cash	561000	usd
CY2022	hlyk	Installments Amount InstallmentsAmount	112200	usd
CY2022	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount	366600	usd
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	224400	usd
CY2022Q4	hlyk	Installments Amount InstallmentsAmount	56100	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.10	pure
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	33752	usd
CY2022	hlyk	Proceeds Of Sales ProceedsOfSales	392700	usd
CY2022	us-gaap	Payments For Participation Liabilities PaymentsForParticipationLiabilities	279415	usd
CY2022Q4	us-gaap	Impaired Financing Receivable Unpaid Principal Balance ImpairedFinancingReceivableUnpaidPrincipalBalance	168300	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4748	usd
CY2022Q4	hlyk	Conversion Right Discount ConversionRightDiscount	0.15	pure
CY2022Q4	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	1221	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	9615	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	31393	usd
CY2016Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	50	usd
CY2016Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	111000	usd
CY2016Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.10	pure
CY2021Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	13538494	shares
CY2022	hlyk	Recognized A Loss On Debt RecognizedALossOnDebt	5463492	usd
CY2022	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	0	usd
CY2021	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	19246	usd
CY2022	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	0	usd
CY2021	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	4372	usd
CY2022Q3	hlyk	Sepa Advances Descriptions SEPAAdvancesDescriptions	the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA Advance may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022.
CY2022	us-gaap	Exchange Fees ExchangeFees	10000	usd
CY2022Q4	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	895255	shares
CY2022Q4	us-gaap	Financing Receivable Deferred Income FinancingReceivableDeferredIncome	100000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	110000	usd
CY2022Q3	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	451202	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5683100	shares
CY2022Q4	hlyk	Promissory Note Balance PromissoryNoteBalance	279415	usd
CY2021Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	3000000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3703704	shares
CY2021Q3	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	0.54
CY2021Q3	hlyk	Aggregate Common Shares AggregateCommonShares	1851852	shares
CY2021Q3	us-gaap	Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares	50	shares
CY2021Q3	hlyk	Warrants Exercise Price WarrantsExercisePrice	0.65
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	269269	shares
CY2021Q3	hlyk	Aggregate Shares Of Percentage AggregateSharesOfPercentage	0.08	pure
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.675
CY2021Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	125
CY2021Q3	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	1719921	usd
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	664076	shares
CY2021	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	2998122	shares
CY2022	hlyk	Schedule Of Common Stock Issuable ScheduleOfCommonStockIssuable	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Shares issuable to employees and consultants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">210,584</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,183,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">319,454</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issuable to independent directors</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,144</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">117,791</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">399,912</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,584</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,585,542</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">282,347</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">719,366</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2022Q4	hlyk	Common Stock Issuables Value CommonStockIssuablesValue	225584	usd
CY2022Q4	hlyk	Common Stock Issuables Shares CommonStockIssuablesShares	2585542	shares
CY2021Q4	hlyk	Common Stock Issuables Value CommonStockIssuablesValue	282347	usd
CY2021Q4	hlyk	Common Stock Issuables Shares CommonStockIssuablesShares	719366	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.2
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16450	usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	145500	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115145	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77793	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	174594	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	135805	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	171399	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	386054	shares
CY2022	hlyk	Warrants Issued During Period WarrantsIssuedDuringPeriod	9392101	shares
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20000000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3111750	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.2
CY2020Q4	hlyk	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	40783	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	580000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.33
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	145500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	90000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.19
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3456250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.2
CY2021Q4	hlyk	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	873096	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2211232	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.1
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	432000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.31
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5222982	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2022Q4	hlyk	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10200	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2962565	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1651435	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.05
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	302050	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.27
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	36270	usd
CY2022	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P1Y7M6D
CY2022	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.05
CY2021	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.21
CY2022	hlyk	Pricing Model Utilized PricingModelUtilized	Binomial Lattice
CY2021	hlyk	Pricing Model Utilized PricingModelUtilized	Binomial Lattice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	hlyk	Nonvested At Beginning Of Period NonvestedAtBeginningOfPeriod	858750	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.23
CY2020Q4	hlyk	Nonvested At Beginning Of Period NonvestedAtBeginningOfPeriod	1044375	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.21
CY2022	hlyk	Granted Granted	2211232	shares
CY2022	hlyk	Weighted Average Grant Date Fair Value Granted WeightedAverageGrantDateFairValueGranted	0.06
CY2021	hlyk	Granted Granted	580000	shares
CY2021	hlyk	Weighted Average Grant Date Fair Value Granted WeightedAverageGrantDateFairValueGranted	0.25
CY2022	hlyk	Vested Vested	-515315	shares
CY2022	hlyk	Weighted Average Grant Date Fair Value Vested WeightedAverageGrantDateFairValueVested	-0.15
CY2021	hlyk	Vested Vested	-707500	shares
CY2021	hlyk	Weighted Average Grant Date Fair Value Vested WeightedAverageGrantDateFairValueVested	-0.22
CY2022	hlyk	Forfeited Forfeited	-294250	shares
CY2022	hlyk	Weighted Average Grant Date Fair Value Forfeited WeightedAverageGrantDateFairValueForfeited	-0.26
CY2021	hlyk	Forfeited Forfeited	-58125	shares
CY2021	hlyk	Weighted Average Grant Date Fair Value Forfeited WeightedAverageGrantDateFairValueForfeited	-0.14
CY2022Q4	hlyk	Nonvested At End Of Period NonvestedAtEndOfPeriod	2260417	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.08
CY2021Q4	hlyk	Nonvested At End Of Period NonvestedAtEndOfPeriod	858750	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.23
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	302050	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.27
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	200000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.17
CY2022	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedGrantsInPeriodGross	3721222	shares
CY2022	hlyk	Granted Weighted Average Grant Date Fair Value GrantedWeightedAverageGrantDateFairValue	0.05
CY2021	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedGrantsInPeriodGross	1496861	shares
CY2021	hlyk	Granted Weighted Average Grant Date Fair Value GrantedWeightedAverageGrantDateFairValue	0.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2266883	shares
CY2022	hlyk	Vested Weighted Average Grant Date Fair Value VestedWeightedAverageGrantDateFairValue	-0.08
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1337311	shares
CY2021	hlyk	Vested Weighted Average Grant Date Fair Value VestedWeightedAverageGrantDateFairValue	-0.19
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	104954	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue	-0.19
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	57500	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue	-0.16
CY2021	hlyk	Liability Classified Equity Instruments Description LiabilityClassifiedEquityInstrumentsDescription	The original grant date fair value of the equity compensation was $165,000. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument.” During the years ended December 31, 2022, the Company (i) replaced certain variable share contracts with a new fixed share compensation structure and accordingly de-recognized $25,000 of deferred stock compensation and liability-classified equity instruments, and (ii) de-recognized $106,141 of deferred stock compensation and $135,000 of liability-classified equity instruments as a result of the termination of the employee and related future equity rights to which the equity asset and liability related.
CY2022Q4	hlyk	Liabilityclassified Equity Instruments LiabilityclassifiedEquityInstruments	90000	usd
CY2022	hlyk	Deferred Stock Amount DeferredStockAmount	13338	usd
CY2022Q4	us-gaap	Workers Compensation Discount Amount WorkersCompensationDiscountAmount	2287	usd
CY2022	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	21771	usd
CY2021	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	13750	usd
CY2022	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 – CONTINGENT ACQUISITION CONSIDERATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contingent acquisition consideration relates to future earn-out payments potentially payable related to the Company’s acquisitions of Hughes Center for Functional Medicine (“HCFM”) in 2019 and CHM and MOD in 2020. The terms of the earn-outs related to each acquisition require the Company to pay the former owners additional acquisition consideration for the achievement of prescribed revenue and/or earnings targets for performance of the underlying business for up to four years after the respective acquisition date. Contingent acquisition consideration for each entity is recorded at fair value using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contingent acquisition consideration as of December 31, 2022 and 2021 was comprised of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Fair value of HCFM contingent acquisition consideration</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">---</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">172,124</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of CHM contingent acquisition consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Fair value of MOD contingent acquisition consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,283</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">737,037</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total contingent acquisition consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,185,690</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: long term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,239</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(782,224</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Contingent acquisition consideration, current portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">100,068</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">403,466</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022 and 2021, the Company recognized gains (losses) on the change in the fair value of contingent acquisition consideration as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">HCFM contingent acquisition consideration</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(35,260</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(66,888</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CHM contingent acquisition consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(86,274</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">MOD contingent acquisition consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">723,754</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(220,494</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779,999</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(373,656</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maturities of contingent acquisition consideration were as follows as of December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,068</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,239</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">198,307</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hughes Center for Functional Medicine Acquisition – April 2019 </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2019, the Company acquired a 100% interest in HCFM, a medical practice engaged in improving the health of its patients through individualized and integrative health care. Under the terms of acquisition, the Company paid the seller $500,000 in cash, issued 3,968,254 shares of the Company’s common stock and agreed to an earn-out provision of $500,000 that may be earned based on the performance of NCFM in the years ended on the first, second and third anniversary dates of the acquisition closing. The total consideration fair value represented a transaction fair value of $1,764,672. In May 2020, the Company paid the seller $47,000 in satisfaction of the year 1 earn out. In May 2021, the Company paid the seller $196,000 in satisfaction of the year 2 earn out. In May 2022, the Company paid the seller $207,384 in satisfaction of the year 3 earn out. The Company has no further earn out obligations related to the NCFM acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MedOffice Direct LLC Acquisition – October 2020 </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 19, 2020, the Company acquired a 100% interest in MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. Under the terms of acquisition, the Company paid the following consideration: (i) 19,045,563 shares of Company common stock issued at closing, (ii) partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash paid by the Company, and (iii) up to 10,004,749 restricted shares of the Company’s common stock over a four-year period based on MOD achieving revenue targets in calendar years 2021, 2022, 2023, and 2024 of $1,500,000, $1,875,000, $2,344,000, and $2,930,000, respectively. The first and second years of earnout measured based on performance in calendar years 2021 and 2022, respectively, were not met. Because the MOD earnout is payable in a fixed number of shares for each earnout year, the fair value of MOD contingent acquisition consideration is dependent in large part on the price of the Company’s stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cura Health Management LLC Acquisition – May 2020</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 18, 2020, the Company acquired a 100% interest in CHM and its wholly owned subsidiary AHP. The acquisition consideration included an earnout of up to $62,500, $125,000, $125,000 and $125,000 cash for years 1, 2, 3, and 4, respectively, based on achievement by the underlying business of revenue of at least $2,250,000 (50% weighting) and profit of at least $500,000 (50% weighting) in the year preceding each anniversary date of the closing (the “Future Earnout”). On January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP.</p>
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	198307	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1185690	usd
CY2022Q4	hlyk	Contingent Acquisition Consideration Long Term Portion ContingentAcquisitionConsiderationLongTermPortion	-98239	usd
CY2021Q4	hlyk	Contingent Acquisition Consideration Long Term Portion ContingentAcquisitionConsiderationLongTermPortion	-782224	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	100068	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	403466	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	779999	usd
CY2021	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	-373656	usd
CY2022	hlyk	Maturitiesofcontingentacquisition Three Years MaturitiesofcontingentacquisitionThreeYears	100068	usd
CY2022	hlyk	Maturities Of Contingent Acquisition Four Years MaturitiesOfContingentAcquisitionFourYears	98239	usd
CY2022	hlyk	Maturities Of Contingent Acquisition Total MaturitiesOfContingentAcquisitionTotal	198307	usd
CY2022	hlyk	Supplier Concentration SupplierConcentration	0.95	pure
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1016900	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022Q4	hlyk	Cash Payment Description CashPaymentDescription	The Agreement was effective as of July 1, 2022 and provides that Mr. O’Leary’s base salary will be $259,000 per year, with annual review and adjustment at the discretion of the Chief Executive Officer and Compensation Committee of the Board of Directors of the Company, and an annual incentive bonus of 25% of annual salary based on the achievement of the Company of certain financial metrics as approved by the Compensation Committee.
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	50000	usd
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	100000	shares
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The act replaced the prior-law graduated corporate tax rate, which taxed income over $10 million at 35%, with a flat rate of 21%.
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8815700	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10412600	usd
CY2022	hlyk	Loss Before Income Tax LossBeforeIncomeTax	-8815700	usd
CY2021	hlyk	Loss Before Income Tax LossBeforeIncomeTax	-10412600	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1851300	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2186700	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	576600	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1041000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-214100	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-192100	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3747800	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	320900	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2259000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8713000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4882000	usd
CY2022	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-176600	usd
CY2021	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-176600	usd
CY2022Q4	hlyk	Change In Fair Value Of Contingent Acquisition Consideration ChangeInFairValueOfContingentAcquisitionConsideration	-118300	usd
CY2021Q4	hlyk	Change In Fair Value Of Contingent Acquisition Consideration ChangeInFairValueOfContingentAcquisitionConsideration	73000	usd
CY2022Q4	hlyk	Loss From Change In Fair Value Of Debts LossFromChangeInFairValueOfDebts	93600	usd
CY2021Q4	hlyk	Loss From Change In Fair Value Of Debts LossFromChangeInFairValueOfDebts	93600	usd
CY2022Q4	hlyk	Right Of Use Lease Asset RightOfUseLeaseAsset	132500	usd
CY2021Q4	hlyk	Right Of Use Lease Asset RightOfUseLeaseAsset	129200	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	133100	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	129500	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	290000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	182100	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8802200	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5054400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	8802200	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	5054400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35500000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	19900000	usd
CY2022	hlyk	Income Tax Loss Carry Forwards IncomeTaxLossCarryForwards	3200000	usd
CY2021	hlyk	Income Tax Loss Carry Forwards IncomeTaxLossCarryForwards	32300000	usd
CY2022	hlyk	Subscriptions Revenues SubscriptionsRevenues	830	usd
CY2021	hlyk	Subscriptions Revenues SubscriptionsRevenues	943	usd
CY2022Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	273307	usd
CY2021Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	1348190	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2022	hlyk	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants		usd
CY2022	hlyk	Fair Value Liabilities Measured On Warrants Unobservable Input Reconciliations Value FairValueLiabilitiesMeasuredOnWarrantsUnobservableInputReconciliationsValue	779999	usd
CY2021	hlyk	Fair Value Liabilities Measured On Warrants Unobservable Input Reconciliations Value FairValueLiabilitiesMeasuredOnWarrantsUnobservableInputReconciliationsValue	-392902	usd
CY2022	hlyk	Reimbursed Amount ReimbursedAmount	500000	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3000000	usd
CY2022	hlyk	Incremental Amount IncrementalAmount	500000	usd
CY2022	us-gaap	Dividends Cash DividendsCash	2250000	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	2000000	shares
CY2023Q1	hlyk	Sale Amount SaleAmount	200000	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	1500000	shares
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.2
CY2022	hlyk	Retirement Amount RetirementAmount	550	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	13972	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent		usd
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	397194	usd
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments		usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255940389	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255940389	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	hlyk	Common Stock Issuable Shares CommonStockIssuableShares	2585542	shares
CY2021Q4	hlyk	Common Stock Issuable Shares CommonStockIssuableShares	719366	shares
CY2022Q4	hlyk	Common Stock Par Value CommonStockParValue	0.0001
CY2021Q4	hlyk	Common Stock Par Value CommonStockParValue	0.0001
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2021	us-gaap	Financing Interest Expense FinancingInterestExpense		usd
CY2021	hlyk	Amortization Of Original Issue Discounts On Notes Payable AmortizationOfOriginalIssueDiscountsOnNotesPayable		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	hlyk	Exercise Of Stock Options Value ExerciseOfStockOptionsValue		usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2021	hlyk	Increase Decrease In Contract Assets IncreaseDecreaseInContractAssets		usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	hlyk	Fair Value Of Shares Issued As Purchase Price Consideration FairValueOfSharesIssuedAsPurchasePriceConsideration		usd
CY2021	hlyk	Net Carrying Value Of Equity Liabilitiesassets Written Off NetCarryingValueOfEquityLiabilitiesassetsWrittenOff		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	hlyk	Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote		usd
CY2021	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Debt FairValueOfWarrantsAllocatedToProceedsOfDebt		usd
CY2021	hlyk	Debt Discount And Original Issue Discount Allocated To Proceeds Of Notes Payable DebtDiscountAndOriginalIssueDiscountAllocatedToProceedsOfNotesPayable		usd
CY2022	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q4	hlyk	Incremental Fair Value Of Warrants Modified To Extend Maturity Date Of Convertible Notes Payable IncrementalFairValueOfWarrantsModifiedToExtendMaturityDateOfConvertibleNotesPayable		usd
CY2022	hlyk	Conversion Of Convertible Notes Payable To Common Stock ConversionOfConvertibleNotesPayableToCommonStock		usd
CY2022Q4	hlyk	Fair Value Of Warrants Issued In Connection With Conversion Of Convertible Notes Payable FairValueOfWarrantsIssuedInConnectionWithConversionOfConvertibleNotesPayable		usd
CY2022	hlyk	Accrued Liabilities Relieved Upon Cashless Exercise Of Warrants AccruedLiabilitiesRelievedUponCashlessExerciseOfWarrants		usd
CY2022	hlyk	Contingent Acquisition Consideration Payable In Common Stock ContingentAcquisitionConsiderationPayableInCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Current DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent		usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent		usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent		usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent		usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent		usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2021Q4	hlyk	Unamortized Discount UnamortizedDiscount		usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001680139

Files In Submission

Name	View Source	Status
hlyk-20221231_cal.xml	Edgar Link	unprocessable
hlyk-20221231_def.xml	Edgar Link	unprocessable
0001213900-23-025432-index-headers.html	Edgar Link	pending
0001213900-23-025432-index.html	Edgar Link	pending
0001213900-23-025432.txt	Edgar Link	pending
0001213900-23-025432-xbrl.zip	Edgar Link	pending
f10k2022ex21-1_healthlynked.htm	Edgar Link	pending
f10k2022ex23-1_healthlynked.htm	Edgar Link	pending
f10k2022ex31-1_healthlynked.htm	Edgar Link	pending
f10k2022ex31-2_healthlynked.htm	Edgar Link	pending
f10k2022ex32-1_healthlynked.htm	Edgar Link	pending
f10k2022ex32-2_healthlynked.htm	Edgar Link	pending
f10k2022_healthlynk.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hlyk-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_healthlynk_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
hlyk-20221231_lab.xml	Edgar Link	unprocessable
hlyk-20221231_pre.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HLYK
HealthLynked Corp Stock $hlyk

2023 Q1 Form 10-K Financial Statement

#000121390023025432 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLYK HealthLynked Corp Stock $hlyk

2023 Q1 Form 10-K Financial Statement

#000121390023025432 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLYK
HealthLynked Corp Stock $hlyk